GlassScriptPhysician profile
Mark S Avila
NPI 1598742058
$9,597.55
in general payments reported to CMS, 2019-2025
42 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,679 · 2020: $953 · 2021: $1,649 · 2022: $1,422 · 2023: $1,332 · 2024: $892 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,776 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,775.53 |
| Education | $119.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $1,541.85 | 2019-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,381.64 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $928.34 | 2019-2025 | |
| Abbvie INC. | $864.09 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $790.19 | 2020-2025 | Stelara, Tremfya |
| Ipsen Biopharmaceuticals, INC | $731.44 | 2024-2025 | Iqirvo, Bylvay |
| Redhill Biopharma INC. | $417.10 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Ardelyx, INC. | $380.01 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $322.65 | 2024-2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $285.69 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $228.79 | 2019-2024 | Eohilia |
| Celgene Corporation | $208.98 | 2019-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $170.66 | 2021 | |
| Napo Pharmaceuticals INC | $168.08 | 2019-2021 | |
| Vivus LLC | $120.46 | 2021-2025 | Qsymia, Pancreaze |
Show all 40 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Avila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.